Exact Sciences Shareholders Overwhelmingly Approve $105-Per-Share Abbott Acquisition
Event summary
- Exact Sciences shareholders voted 99% in favor of the Abbott acquisition, with 67% of outstanding shares represented.
- The deal, valued at $105 per share in cash, is expected to close by Q2 2026.
- Exact Sciences' portfolio includes Cologuard, Oncotype DX, Cancerguard, and Oncodetect.
- Final voting results will be reported in an SEC Form 8-K filing.
The big picture
The acquisition positions Abbott to strengthen its diagnostics business with Exact Sciences' cancer screening and monitoring technologies. This deal reflects a broader trend of consolidation in the precision medicine space, as larger healthcare players seek to expand their capabilities in early cancer detection and personalized treatment. The $105-per-share price tag underscores the strategic value of Exact Sciences' portfolio, particularly its multi-cancer early detection test, Cancerguard.
What we're watching
- Regulatory Approval
- Whether remaining regulatory conditions will delay or derail the transaction timeline.
- Integration Strategy
- How Abbott plans to integrate Exact Sciences' diagnostic portfolio into its existing healthcare solutions.
- Competitive Response
- The pace at which competitors may accelerate their own diagnostic innovations or M&A efforts.
Related topics